|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim HY and Park JW: Clinical trials of
combined molecular targeted therapy and locoregional therapy in
hepatocellular carcinoma: Past, present, and future. Liver Cancer.
3:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Njei B, Rotman Y, Ditah I and Lim JK:
Emerging trends in hepatocellular carcinoma incidence and
mortality. Hepatology. 61:191–199. 2015. View Article : Google Scholar
|
|
4
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lazarevich NL, Cheremnova OA, Varga EV,
Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI,
Engelhardt NV and Duncan SA: Progression of HCC in mice is
associated with a downregulation in the expression of hepatocyte
nuclear factors. Hepatology. 39:1038–1047. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanaka S and Arii S: Molecular targeted
therapies in hepatocellular carcinoma. Semin Oncol. 39:486–492.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fry AM: The Nek2 protein kinase: A novel
regulator of centrosome structure. Oncogene. 21:6184–6194. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Faragher AJ and Fry AM: Nek2A kinase
stimulates centrosome disjunction and is required for formation of
bipolar mitotic spindles. Mol Biol Cell. 14:2876–2889. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bahe S, Stierhof YD, Wilkinson CJ, Leiss F
and Nigg EA: Rootletin forms centriole-associated filaments and
functions in centrosome cohesion. J Cell Biol. 171:27–33. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hayward DG, Clarke RB, Faragher AJ, Pillai
MR, Hagan IM and Fry AM: The centrosomal kinase Nek2 displays
elevated levels of protein expression in human breast cancer.
Cancer Res. 64:7370–7376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R,
Lau J, Chen PL and Lee WH: Small molecule targeting the Hec1/Nek2
mitotic pathway suppresses tumor cell growth in culture and in
animal. Cancer Res. 68:8393–8399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsunoda N, Kokuryo T, Oda K, Senga T,
Yokoyama Y, Nagino M, Nimura Y and Hamaguchi M: Nek2 as a novel
molecular target for the treatment of breast carcinoma. Cancer Sci.
100:111–116. 2009. View Article : Google Scholar
|
|
14
|
Wang S, Li W, Lv S, Wang Y, Liu Z, Zhang
J, Liu T and Niu Y: Abnormal expression of Nek2 and β-catenin in
breast carcinoma: Clinicopathological correlations. Histopathology.
59:631–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Vos S, Hofmann WK, Grogan TM, Krug U,
Schrage M, Miller TP, Braun JG, Wachsman W, Koeffler HP and Said
JW: Gene expression profile of serial samples of transformed B-cell
lymphomas. Lab Invest. 83:271–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neal CP, Fry AM, Moreman C, McGregor A,
Garcea G, Berry DP and Manson MM: Overexpression of the Nek2 kinase
in colorectal cancer correlates with beta-catenin relocalization
and shortened cancer-specific survival. J Surg Oncol. 110:828–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ning Z, Wang A, Liang J, Liu J, Zhou T,
Yan Q and Wang Z: Abnormal expression of Nek2 in pancreatic ductal
adenocarcinoma: A novel marker for prognosis. Int J Clin Exp
Pathol. 7:2462–2469. 2014.PubMed/NCBI
|
|
18
|
Zhong X, Guan X, Dong Q, Yang S, Liu W and
Zhang L: Examining Nek2 as a better proliferation marker in
non-small cell lung cancer prognosis. Tumour Biol. 35:7155–7162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ozsolak F and Milos PM: RNA sequencing:
Advances, challenges and opportunities. Nat Rev Genet. 12:87–98.
2011. View
Article : Google Scholar :
|
|
21
|
Sultan M, Schulz MH, Richard H, Magen A,
Klingenhoff A, Scherf M, Seifert M, Borodina T, Soldatov A,
Parkhomchuk D, et al: A global view of gene activity and
alternative splicing by deep sequencing of the human transcriptome.
Science. 321:956–960. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferreira PG, Jares P, Rico D, Gómez-López
G, Martínez-Trillos A, Villamor N, Ecker S, González-Pérez A,
Knowles DG, Monlong J, et al: Transcriptome characterization by RNA
sequencing identifies a major molecular and clinical subdivision in
chronic lymphocytic leukemia. Genome Res. 24:212–226. 2014.
View Article : Google Scholar :
|
|
23
|
Rezaeian I, Tavakoli A, Cavallo-Medved D,
Porter LA and Rueda L: A novel model used to detect differential
splice junctions as biomarkers in prostate cancer from RNA-Seq
data. J Biomed Inform. 60:422–430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang Q, Lin B, Liu H, Ma X, Mo F, Yu W,
Li L, Li H, Tian T and Wu D: RNA-Seq analyses generate
comprehensive transcriptomic landscape and reveal complex
transcript patterns in hepatocellular carcinoma. PLoS One.
6:e261682011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xavier LL, Viola GG, Ferraz AC, Da Cunha
C, Deonizio JM, Netto CA and Achaval M: A simple and fast
densitometric method for the analysis of tyrosine hydroxylase
immunoreactivity in the substantia nigra pars compacta and in the
ventral tegmental area. Brain Res Brain Res Protoc. 16:58–64. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Das TK, Dana D, Paroly SS, Perumal SK,
Singh S, Jhun H, Pendse J, Cagan RL, Talele TT and Kumar S:
Centrosomal kinase Nek2 cooperates with oncogenic pathways to
promote metastasis. Oncogenesis. 2:e692013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou W, Yang Y, Xia J, Wang H, Salama ME,
Xiong W, Xu H, Shetty S, Chen T and Zeng Z: NEK2 induces drug
resistance mainly through activation of efflux drug pumps and is
associated with poor prognosis in myeloma and other cancers. Cancer
Cell. 23:48–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chien CS, Shen KH, Huang JS, Ko SC and
Shih YW: Antimetastatic potential of fisetin involves inactivation
of the PI3K/Akt and JNK signaling pathways with downregulation of
MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell
Biochem. 333:169–180. 2010. View Article : Google Scholar
|
|
29
|
O'Connell MJ, Krien MJ and Hunter T: Never
say never. The NIMA-related protein kinases in mitotic control.
Trends Cell Biol. 13:221–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Q, Hirohashi Y, Du X, Greene MI and
Wang Q: Nek2 targets the mitotic checkpoint proteins Mad2 and
Cdc20: A mechanism for aneuploidy in cancer. Exp Mol Pathol.
88:225–233. 2010. View Article : Google Scholar :
|
|
31
|
Gräf R: DdNek2, the first non-vertebrate
homologue of human Nek2, is involved in the formation of
microtubule-organizing centers. J Cell Sci. 115:1919–1929.
2002.PubMed/NCBI
|
|
32
|
Prigent C, Glover DM and Giet R:
Drosophila Nek2 protein kinase knockdown leads to centrosome
maturation defects while overexpression causes centrosome
fragmentation and cytokinesis failure. Exp Cell Res. 303:1–13.
2005.
|
|
33
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014.
|
|
34
|
Naro C, Barbagallo F, Chieffi P, Bourgeois
CF, Paronetto MP and Sette C: The centrosomal kinase NEK2 is a
novel splicing factor kinase involved in cell survival. Nucleic
Acids Res. 42:3218–3227. 2014. View Article : Google Scholar :
|
|
35
|
Takahashi Y, Iwaya T, Sawada G, Kurashige
J, Matsumura T, Uchi R, Ueo H, Takano Y, Eguchi H, Sudo T, et al:
Up-regulation of NEK2 by microRNA-128 methylation is associated
with poor prognosis in colorectal cancer. Ann Surg Oncol.
21:205–212. 2014. View Article : Google Scholar
|
|
36
|
Marina M and Saavedra HI: Nek2 and Plk4:
Prognostic markers, drivers of breast tumorigenesis and drug
resistance. Front Biosci (Landmark Ed). 19:352–365. 2014.
View Article : Google Scholar
|
|
37
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar
|
|
38
|
Li J, Lau GK, Chen L, Dong SS, Lan HY,
Huang XR, Li Y, Luk JM, Yuan YF and Guan XY: Interleukin 17A
promotes hepatocellular carcinoma metastasis via NF-κB induced
matrix metalloproteinases 2 and 9 expression. PLoS One.
6:e218162011. View Article : Google Scholar
|
